Refi ning genetic associations in multiple sclerosis
Genome-wide association studies involve several hundred thousand markers and, even when quality control is scrupulous, are invariably confounded by residual uncorrected errors that can falsely infl ate the apparent diff erence between cases and controls (socalled genomic infl ation). 1 As a consequence such studies inevitably generate false positives alongside genuine associations. By use of Bayesian logic and empirical data, the Wellcome Trust Case Control Consortium suggested that association studies in complex disease should involve at least 2000 cases and 2000 controls, at which level they predicted that p values of less than 5×10 -7 would more commonly signify true positives than false positives. 2 cannot be drawn confi dently without a placebocontrolled (sham surgery) trial, the ethics of which are debatable and which might not be practical because stimulation eff ects might prevent blinding. A study that compares DBS with the eff ects of implanted but temporarily inactivated electrodes could further diff erentiate the eff ects of surgery versus stimulation.
Additionally, the test battery used in this study, although practical, was restricted, particularly in terms of the executive functions that were assessed. Owing to the stringent selection criteria (no current or previous major psychiatric illness or cognitive impairment), the rates of serious psychiatric and cognitive adverse events in this study are not trivial. Indeed, the rates of serious psychiatric adverse events (and marked cognitive decline as per Mattis dementia rating scale score) are high for such a short (6-month) follow-up interval in a highly selected sample when the typical incidence of serious psychiatric and cognitive changes in patients with PD over a year are considered.
The results of this study, like those of other hitherto unsuccessful investigations, fail to fi nd a signifi cant association between neurobehavioural changes and changes in drug dose, but the authors did not examine the potential role of stimulation and other disease and demographic parameters (the range of which might have been restricted by stringent selection, potentially precluding identifi cation of signifi cant correlations). Consequently, the identifi cation of risk factors for neurobehavioural decline after DBS in a minority of patients is elusive.
The initial observation in a few small, uncontrolled studies that improvements in motor symptoms and quality of life might not translate into social readjustment deserves urgent investigation.
9,10 Future research will need to identify the patient-related, medicosurgical, and psychosocial factors that preclude gains in occupational, interpersonal, familial, and marital functioning in some patients, and the barriers to coping and societal reintegration. Also, assuming DBS to be safe, should the current exclusion criteria for neurobehavioural studies be relaxed? This could allow more patients to access to a potentially life-improving treatment and enable the identifi cation of the risk factors for neurobehavioural decline in patients whose selection perhaps more closely mirrors clinical practice outside of clinical trials. The screening phase of our recent multiple sclerosis genome-wide association study 3 involved just 931 trio families and thus fell short of the minimum power recommended by the Wellcome Trust Case Control Consortium. However, the extension phase of our study included 2322 cases, 5418 controls, and 1540 trio families (12 360 individuals in total) and identifi ed three markers exceeding the consortium's threshold -rs6897932 in IL7R (p=2·94×10 -7) and rs12722489 and rs2104286 in IL2RA (p=2·96x10 -8 and 2·16x10 -7 respectively). These markers showed modest levels of signifi cance in the screening phase of the study (p values 0·0058, 0·0013, and 0·0033, respectively). In overlapping 4 and independent 5 data sets, we simultaneously identifi ed association with IL7R (rs6897932) through a candidate gene approach. IL2RA was suggested as a candidate by its confi rmation as a susceptibility gene for type 1 diabetes. 2 The extensive linkage disequilibrium between rs12722489 and rs2104286 in the IL2RA gene meant that it was impossible to determine whether one or other locus exerts a primary eff ect or whether both infl uence risk.
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The three identifi ed loci have several similarities. For each the more common (major) allele increases susceptibility, and in each case the risk exerted by this allele is modest (with odds ratios about 1·2). All three of these single-nucleotide polymorphisms have been studied in the HapMap cohorts and curiously in each case the risk allele is even more common in non-white ethnic groups. Because multiple sclerosis is more common in white people than in other ethnic groups, this reverse pattern of allele frequency is a reminder that these alleles account for only a fraction of the heritable infl uences on susceptibility.
To refi ne our understanding of these associations, we typed all three variants in an additional 20 708 individuals in Australia, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway, Sardinia, Spain, Sweden, and new samples from the UK (webappendix). Together with the 12 360 reported in our original screen this provides a total of 33 068 individuals, including 11 019 unrelated cases, 13 616 controls and 2811 trio families (8433 individuals). All individuals involved in this study gave informed consent under appropriate local ethical approval. Overall genotyping effi ciency was 98·4% for rs6897932, 95·4% for rs12722489, and 95·7% for rs2104286. None of the three markers showed any signifi cant evidence for deviation from Hardy-Weinberg equilibrium in the controls although deviation was seen in the cases, as expected for genuine associations (webappendix).
In total, 20 population-specifi c cohorts (14 case-control and six trio family) were considered. Nominally signifi cant association was observed in eight for rs6897932, in nine for rs12722489, and in 13 for rs2104286. In all but three studies, the risk allele as defi ned in our original screen (ie, the major allele at each locus) was over-represented in cases. None of these three negative fi ndings (Australia and Ireland for rs6897932, and Holland for rs12722489) was signifi cant. In short, all signifi cant studies were in accordance with the original screen and most in which there was no statistically signifi cant association implicated the major allele as expected. Results for the individual studies are shown in the webappendix. In the control groups, major-allele frequency was 64-77% for rs6897932, 77-90% for rs12722489, and 69-83% for rs2104286. However, applying the Breslow-Day test confi rms that there is no evidence of heterogeneity of eff ect across the populations for any of the markers. Thus, although the frequency of the risk allele shows modest variation between white populations, the eff ects of these alleles are of undoubted relevance (table) . 6, 7 We confi rmed linkage disequilibrium between the two polymorphisms in IL2RA (r²=0·5). Conditioning on each marker in turn shows that the association seen at rs12722489 is entirely a consequence of its linkage disequilibrium with rs2104286. This fi nding confi rms that rs2104286 (or another single-nucleotide polymorphism in linkage disequilibrium with it) is the primary association even though it showed less signifi cant association than rs12722489 in the original screen. Testing for association at the genotypic level confi rms that the homozygous risk genotype confers a signifi cantly greater risk than the heterozygous genotype for both rs6897932 and rs2104286 (webappendix).
This extension analysis illustrates the value of data sets that are signifi cantly larger than the minimum recommended by the Wellcome Trust Case Control Consortium. Although these data convincingly replicate these associations, they do not establish these particular variants as causative. Fine mapping and functional studies will be required.
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